Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a sell rating to a strong-buy rating in a research report sent to investors on Friday. Zacks Investment Research currently has $380.00 price target on the biopharmaceutical company’s stock.
According to Zacks, “Regeneron’s fourth-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea sales. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales in 2018. The action date set by the FDA is Aug 11, 2018. The approval of new drugs like Kevzara and Dupixent provides a significant boost. Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. Kevzara is also expected to pick up further. Even though sales of Praluent have failed to impress to date, we expect the same to gain traction as the year progresses. A potential approval of PD-1 antibody cemiplimab, in advanced cutaneous squamous cell carcinoma will further boost prospects. However, shares of the company have underperformed the industry in the last 12 months.”
REGN has been the topic of a number of other research reports. Barclays lowered shares of Regeneron Pharmaceuticals from an equal weight rating to an underweight rating and cut their price target for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Jefferies Group reissued a hold rating and issued a $421.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, February 2nd. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the stock an equal weight rating in a report on Friday, February 9th. JPMorgan Chase & Co. reissued a hold rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th. Finally, Guggenheim set a $530.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a buy rating in a report on Friday, February 9th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $457.03.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at $332.15 on Friday. The company has a market cap of $35,690.00, a price-to-earnings ratio of 32.19, a P/E/G ratio of 1.04 and a beta of 1.47. Regeneron Pharmaceuticals has a 52-week low of $313.53 and a 52-week high of $543.55. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The firm’s revenue was up 28.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.04 EPS. analysts forecast that Regeneron Pharmaceuticals will post 19.2 earnings per share for the current year.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.80% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Ark Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 78.8% in the second quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 544 shares during the last quarter. Virtu KCG Holdings LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $206,000. Cubist Systematic Strategies LLC raised its holdings in Regeneron Pharmaceuticals by 176.1% in the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 428 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 13.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,212 shares of the biopharmaceutical company’s stock worth $1,578,000 after buying an additional 378 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $713,000. 64.67% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals (REGN) Rating Increased to Strong-Buy at Zacks Investment Research” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/20/regeneron-pharmaceuticals-regn-rating-increased-to-strong-buy-at-zacks-investment-research.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.